Clinical Trial Update: Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations [Phase 3]

View source ↗

Summary

Phase 3 trial of BGJ398 (infigratinib) in first-line cholangiocarcinoma with FGFR2 fusions has been terminated and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• BGJ398 (Infigratinib) (infigratinib)

Snippet

Sponsor: QED Therapeutics, a BridgeBio company | Conditions: Advanced Cholangiocarcinoma, FGFR2 Gene Mutation | Phase 3 | Status: TERMINATED | Results posted: 2024-05-08